Leucovorin, Cisplatin, and 5-Fluorouracil for Advanced Esophageal Cancer
Biochemical modulation involves the use of one drug (modulating agent; modulator) to change the pharmacokinetics and/or pharmacodynamics of a cytotoxic agent (effector), in a way that the therapeutic index of the effector is enhanced . The modulator is often also a cytotoxic agent, but a non-cytotoxic agent like leucovorin is sometimes used as well. The modulating agent improves selectivity or sensitivity of an effector and decreases its toxicity to normal cells via a biochemical or metabolical mechanism. Currently, several biochemical modulations such as the sequential methotrexate (MTX)/5-fluorouracil (5-FU), leucovorin (LV)/5-FU, and cisplatin (CDDP)/5-FU have been evaluated clinically in terms of their efficacy for alimentary tract malignancies.
KeywordsEsophageal Cancer Squamous Cell Cancer Thoracic Esophagus Modulate Agent Advanced Esophageal Cancer
Unable to display preview. Download preview PDF.
- 1.Howell SB (1986) Biochemical modulation: Current status and considerations for the future. In: Kimura K, Yamada K, Krakoff IH, Carter SK (eds) Cancer Chemotherapy—challenges for the future. Excerpta Medica, pp 108–116Google Scholar
- 5.Clark J, Dreyfuss A, Norris C, Busse P, Miller D, Lucarini J, Andersen J, Casey D, Frei E (1990) Continuous infusion cisplatin, 5-FU and high-dose leucovorin (PEL): favorable early results as induction therapy for squamous cell carcinoma of the head and neck. Proc ASCO 9: 172Google Scholar
- 7.Hayashi K, Ide H, Shinoda M, Fukushima M (1992) Phase II study of cisplatin (CDDP) plus 5-fluorouracil (5-FU) and leucovorin ( LCV) for squamous cell carcinoma of the esophagus. Proc ASCO 11: 178Google Scholar